Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Share News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Regent Pacific To Acquire Plethora Solutions For GBP114.3 Million

Tue, 15th Dec 2015 13:47

LONDON (Alliance News) - Regent Pacific Group Ltd on Tuesday said it has agreed to acquire the shares it doesn't already own in Plethora Solutions Holdings PLC, valuing the premature ejaculation treatment company at 11.65 pence per share.

The deal values Plethora at about GBP95.9 million, based on the number of shares in issue, and at GBP114.3 million when considering its fully diluted share capital. Shareholders in Plethora will receive 15.7076 new Regent Pacific shares for each Plethora share they own. Shares in Plethora jumped by 18% to 5.30p on Tuesday afternoon.

The deal comes about six weeks after the companies said they had agreed on the key terms of a possible deal.

James Mellon is the non-executive chairman of Plethora and non-executive co-chairman of Regent Pacific, and Jamie Gibson is an executive director and the chief executive of both companies. Plethora's main product is PSD502, a treatment for premature ejaculation.

On completion of the offer, Plethora shareholders other than Regent Pacific will own about 65.98% of the combined group.

"This offer is about optimising growth and realising the potential of an innovative product that can address a known medical condition affecting almost one in four men. With increased investment and commercial innovation, we see huge scope for the product initially in Europe where it has approval, and in the important US market and in the fast growing Asian market in due course," James Mellon said.

"We view the offer as taking account of PSD502TM's prospects, while also providing a compelling premium of more than 38% to the price at which Plethora's last issued shares in August 2014 and we believe it will create significantly more future value than Plethora could achieve independently," Mellon added.

Michael Wyllie, chief science officer at Plethora, said the deal presents an "achievable solution to its difficult financial position whilst providing shareholders an opportunity to maintain an ongoing economic interest in Plethora and its product".

By Samuel Agini; samagini@alliancenews.com; @samuelagini

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
23 Dec 2015 09:39

Plethora Agrees GBP1.0 Million Loan Facility With Buyer Regent Pacific

Read more
22 Dec 2015 12:02

Port Erin Biopharma Continues To Look For Investments, Swings To Loss

Read more
15 Dec 2015 13:57

Plethora Solutions recommends GBP96m Regent Pacific offer

(ShareCast News) - Plethora Solutions, which is developing a treatment for premature ejaculation, has agreed on a takeover by Hong Kong-listed Regent Pacific that values the AIM company at roughly £96m or 11.65p per share. At Regent Pacific's closing price on Monday, this valued Plethora at a level

Read more
4 Nov 2015 12:19

LONDON MARKET MIDDAY: US Stocks Seen Up Ahead Of Data, Earnings

Read more
4 Nov 2015 10:32

Plethora Solutions Shares Soar, Agrees Regent Pacific Takeover Terms

Read more
4 Nov 2015 10:31

WINNERS & LOSERS SUMMARY: Housebuilders And Estate Agents Torn Down

Read more
28 Aug 2015 15:36

Plethora Interim Loss Narrows As Product Development Continues

Read more
5 Jun 2015 11:30

Plethora Ends Deal With Sharwood, Substitutes Deal With Regent Pacific

Read more
12 May 2015 08:43

Plethora Solutions Appoints New CFO, Non-Executive Director

Read more
30 Mar 2015 12:15

Port Erin Biopharma Swings To First Half Loss As Gains Do Not Recur

Read more
11 Nov 2014 10:48

Plethora Says Fortacin Prescription Sales May Hit USD1 Billion A Year

Read more
10 Nov 2014 09:50

Plethora Solutions Continues Progress Towards Launch Of Fortacin

Read more
7 Oct 2014 08:50

Plethora Solutions' Treatment To Be Marketed As Fortacin In EU

Read more
29 Sep 2014 13:40

Plethora Says Forest Nominees To Convert Loan Notes Into Shares (ALLISS)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.